Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/02/2025 12:42 PDT] Ayala Pharmaceuticals, Inc. (OTC:ADXS), Up By 100% ($0.03) From $0.03 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [07/02/2025 08:07 PDT] ADXS Expected to Trade Up After Bullish Patterns Develop
• [06/30/2025 07:09 PDT] ADXS Expected to Trade Down After Bearish Patterns Develop
• [06/04/2025 11:07 PDT] Ayala Pharmaceuticals, Inc. (OTC:ADXS), Up By 100% ($0.04) From $0.04 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/15/2025 06:53 PDT] ADXS Expected to Trade Up After Bullish Patterns Develop
• [05/05/2025 07:20 PDT] ADXS Expected to Trade Up After Bullish Patterns Develop